Evidence map›Paper›PMID 33900207›Full record

ArticleEar and hearing

Blood Prestin Levels in Normal Hearing and in Sensorineural Hearing Loss: A Scoping Review.

Eleftheria Iliadou, Dimitrios Kikidis, Konstantinos Pastiadis, Christopher J Plack, Athanasios Bibas

Open access · hybridAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Ear and hearing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  2. Article
  3. Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024
    Article
  4. Article
  5. Blood prestin levels in COVID-19 patients.Journal of the Chinese Medical Association : JCMA · 2023
    Article
  6. Integrating pharmacogenomics into clinical trials of hearing disorders.The Journal of the Acoustical Society of America · 2022
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Eleftheria Iliadou1st University ENT Department, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios Kikidis1st University ENT Department, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Konstantinos Pastiadis1st University ENT Department, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Christopher J PlackDepartment of Psychology, Lancaster University, Lancaster, United Kingdom.
Athanasios Bibas1st University ENT Department, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRLancaster University · GB

Funding

Department of Health
6 · The paper itself

Abstract

objectivesRecently, it has been hypothesized that blood prestin concentration levels may reflect cochlear damage and thus serve as an easily measurable, early sensorineural hearing loss (HL) biomarker. This is a scoping review aiming to identify and critically appraise current evidence on prestin blood levels and their temporal variation in rodents and humans with normal hearing and with sensorineural HL.

designThis study was designed and held according to PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. With no limitation with regards to study type, animal and human studies focusing on prestin blood levels in normal hearing and in sensorineural HL were sought in major databases such as Medline, Central Scopus, PROSPERO, and Clinicaltrials.gov. Results were then hand-searched. A data charting form was developed including the parameters of interest.

resultsSeven studies focusing on measuring prestin blood levels by means of ELISA in rodents and human subjects with normal hearing and noise-induced, drug-induced, or idiopathic sudden HL were found eligible and were included in the analysis. According to these proof-of-concept studies, prestin can be detected in the circulation of subjects with no HL; however, normal ranges remain unclear. After cochlear damage, blood prestin levels seem to initially rise and then return to near or below baseline. The degree of their change relates with subjects' degree of HL, damaged cochlear region and recovery. Prestin blood levels and their temporal variation seem to correlate with cochlear damage; however, methodological weaknesses, such as small sample size, lack of detailed phenotyping, insufficient exclusion of confounding factors, and short follow-up, do not allow for robust conclusions.

conclusionsCurrent findings support the value of studying blood prestin levels in normal hearing and HL and highlight a need for larger-scale longitudinal research.

Indexed as

Hearing Loss, SensorineuralAnimalsBiomarkersCochleaHearingNoiseBiomarkers

Identifiers

PMID33900207
PMCPMC8378539
OpenAlexW3132054416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.